Endogenous Cushing's syndrome and cancer risk
Main finding · Any malignancyResult — go to the resultHazard ratio 1.78 95% CI 1.44–2.20Authors' conclusion
Endogenous CS is associated with increased malignancy risk. These findings underscore the need for further research to establish recommendations for cancer screening in this population.
Study context
- Population
- Patients with endogenous Cushing's syndrome (CS), Clalit Health Services database, Israel; mean age at diagnosis 48.0 ± 17.2 years; 2371 (65.4%) womenmatched cohort
- Participants
- 609 vs 3,018
- Exposure
- Endogenous CS vs matched controls
- CSn = 609
- Controlsn = 3,018reference
- Outcome
- First diagnosis of any malignancy following CS diagnosis
- Follow-up
- Median 14.7 years (IQR, 9.9-20.2 years)
Methodological detailsnationwide, matched 1:5 for age, sex, socioeconomic status and BMI, competing-risk Cox model (death as competing event)
- Nationwide
- Matched 1:5 for age, sex, socioeconomic status and BMI
- Competing-risk Cox model (death as competing event)
Main finding
Any malignancy
Hazard ratio
1.78
95% CI 1.44–2.20
CSvs Controls
HR 1.78 (95% CI 1.44–2.20)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | CScases | Controls | HR (95% CI) | |
|---|---|---|---|---|
| Any malignancy, Cushing's disease subgroupCushing's disease | 251 | 1246 controls | 1.65 (1.15–2.36) | |
| Any malignancy, adrenal CS subgroupAdrenal CS | 200 | 991 controls | 2.36 (1.70–3.29) | |
| 0.20.5125Hazard ratio (log scale) |
Cancer risk excluding thyroid malignancies
- Increased cancer risk in CS persists after exclusion of thyroid malignancies
Original publication
Endogenous Cushing's syndrome and cancer risk. Eur J Endocrinol. Published 27 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →